Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 4/20 | 0.35 |
| ▸ | ACP1 | P24666 | 4/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287583 | 0.95 | USP19 (0.36) | USP19ACP1HCRTR1HCRTR2GABRG2 | |
| SCHEMBL4281931 | 0.95 | USP19 (0.36) | USP19ACP1HCRTR1HCRTR2CHRM3 | |
| Fumaric Acid SCHEMBL4289618 | 0.92 | USP19 (0.34) | USP19ACP1HCRTR1HCRTR2 | |
| Fumaric Acid SCHEMBL4289610 | 0.92 | USP19 (0.34) | USP19ACP1HCRTR1HCRTR2 | |
| SCHEMBL4289876 | 0.90 | USP19 (0.37) | USP19ACP1HCRTR1HCRTR2CHRM3 | |
| SCHEMBL4285874 | 0.90 | USP19 (0.37) | USP19ACP1HCRTR1HCRTR2 | |
| SCHEMBL4289852 | 0.89 | USP19 (0.35) | USP19ACP1HCRTR1HCRTR2 | |
| SCHEMBL4288961 | 0.88 | USP19 (0.37) | USP19ACP1HCRTR1HCRTR2CHRM3 | |
| SCHEMBL4290423 | 0.87 | USP19 (0.36) | USP19ACP1HCRTR1HCRTR2CHRM3 | |
| SCHEMBL4287292 | 0.87 | USP19 (0.35) | USP19ACP1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156485-A1 | METHOD FOR COUPLING KERATIN-BINDING POLYPEPTIDES WITH EFFECTOR MOLECULES WHICH SUPPORT CARBOXYLIC GROUPS OR SULFONIC ACID GROUPS | BASE SE (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP19 1993/4885ACP1 3629/4885HCRTR1 3147/4885 |
| US-20090156485-A1 | METHOD FOR COUPLING KERATIN-BINDING POLYPEPTIDES WITH EFFECTOR MOLECULES WHICH SUPPORT CARBOXYLIC GROUPS OR SULFONIC ACID GROUPS | KRT18, KRTCAP2, CUTA | USP19 2608/4885ACP1 162/4885HCRTR1 4486/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP19 1993/4885ACP1 3629/4885HCRTR1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.